[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版). 现代医学卫生, 2018, 34: 641-649.
[2] Zhou Q,Wang Y,Wang J,et al. Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medicine (Baltimore), 2021, 100: e24940.
[3] Frager SZ,Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol, 2020, 27: 138-143.
[4] Gautheron J,Gores GJ,Rodrigues CMP. Lytic cell death in metabolic liver disease. J Hepatol, 2020, 73: 394-408.
[5] Mohammed S,Nicklas EH,Thadathil N,et al. Role of necroptosis in chronic hepatic inflammation and fibrosis in a mouse model of increased oxidative stress. Free Radic Biol Med, 2021, 164: 315-328.
[6] Sharma BR,Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol, 2021,22:550-559.
[7] Al Mamun A,Wu Y,Jia C,et al. Role of pyroptosis in liver diseases. Int Immunopharmacol, 2020, 84: 106489.
[8] Miao EA,Rajan JV,Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev, 2011, 243: 206-214.
[9] Starobova H,Monteleone M,Adolphe C,et al. Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release. J Exp Med, 2021, 218:e20201452.
[10] Khan I,Yousif A,Chesnokov M,et al. A decade of cell death studies: breathing new life into necroptosis. Pharmacol Ther, 2021, 220: 107717.
[11] Makoni NJ,Nichols MR. The intricate biophysical puzzle of caspase-1 activation. Arch Biochem Biophys, 2021, 699: 108753.
[12] Sun L,Ma W,Gao W,et al. Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome. Cell Death Dis, 2019, 10: 542.
[13] Lozano-Ruiz B,Gonzalez-Navajas JM. The emerging relevance of AIM2 in liver disease. Int J Mol Sci, 2020, 21:6535.
[14] Wu J,Sun J,Meng X. Pyroptosis by caspase-11 inflammasome-Gasdermin D pathway in autoimmune diseases. Pharmacol Res, 2021, 165: 105408.
[15] 周青丽,许真源,张素妍,等. NOD样蛋白3炎症小体在非酒精性脂肪性肝炎中的作用. 临床肝胆病杂志, 2019, 35: 1380-1383
[16] Mitsuyoshi H,Yasui K,Hara T,et al. Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease. Hepatol Res, 2017, 47: 1459-1468.
[17] de Sant'Ana LP,Ribeiro DJS,Martins AMA,et al. Absence of the caspases 1/11 modulates liver global lipid profile and gut microbiota in high-fat-diet-induced obese mice. Front Immunol, 2019, 10: 2926.
[18] Xu L,Zhou J,Che J,et al. Mitochondrial DNA enables AIM2 inflammasome activation and hepatocyte pyroptosis in non-alcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol, 2021,320:G1034-G1044.
[19] Ramai D,Tai W,Rivera M,et al. Natural progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Biomedicines, 2021, 9:184.
[20] Zhang NP,Liu XJ,Xie L,et al. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. Lab Invest, 2019, 99: 749-763.
[21] Liu J,Wang T,He K,et al. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation. Eur Rev Med Pharmacol Sci, 2019, 23: 8158-8167.
[22] Xu B,Jiang M,Chu Y,et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J Hepatol, 2018, 68: 773-782.
[23] Gaul S,Leszczynska A,Alegre F,et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol, 2021, 74: 156-167.
[24] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology, 2018, 67: 328-357.
[25] Ezquerro S,Mocha F,Fruhbeck G,et al. Ghrelin reduces TNF-alpha-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD. J Clin Endocrinol Metab, 2019, 104: 21-37.
[26] Qu J,Yuan Z,Wang G,et al. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice. Int Immunopharmacol, 2019, 70: 147-155.
[27] Yu X,Hao M,Liu Y,et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. Eur J Pharmacol, 2019, 864: 172715.
[28] Wang X,Sun K,Zhou Y,et al. NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice. Biochem Biophys Res Commun, 2021,534:734-739.
[29] Yang G,Jang JH,Kim SW,et al. Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasome. Int J Mol Sci, 2020, 21:2790.
[30] Yen IC,Lin JC,Chen Y,et al. Antrodia Cinnamomea Attenuates Non-Alcoholic Steatohepatitis by Suppressing NLRP3 Inflammasome Activation In Vitro and In Vivo. Am J Chin Med, 2020,48: 1859-1874.
[31] Han R,Qiu H,Zhong J,et al. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota. Phytomedicine, 2021, 85: 153544. |
